Biophytis Receives Approval Of Bpifrance For An Innovation Loan Of €1.1 Million To Finance The SARA-PK Trial

Romainville, July 29th, 2016 – BIOPHYTIS (Alternext Paris : ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announced that is has received approval of bpifrance for a 1.1 million euros innovation loan to finance the pharmacokinetic trial of Sarconeos (SARA-PK). Sarconeos is a drug candidate in the treatment of sarcopenic obesity.

The conditional advance granted by bpifrance will complement the funding of the SARA-PK trial. SARA-PK received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) and the Ethics Committee in Antwerp, enabling its initiation.

This trial will be conducted in two phases during the second half of 2016 and will assess pharmacokinetics and safety of Sarconeos in elderly healthy volunteers (> 65 years old). The results of the trial will support the clinical and regulatory filing for Sarconeos, required for authorization of the SARA-INT clinical study (Phase 2b) initiation, currently scheduled to start in the first half of 2017 in target countries (France, Belgium, Italy and USA).

With this funding, Biophytis will be able to fully conduct the SARA-PK study while preparing the next stages of Sarconeos’ development.

Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, declares: « We are pleased to obtain this financing, which demonstrates the support and interest our research is generating. This trial is the first step towards a first treatment for sarcopenia, a pathology affecting 50 million people worldwide and for which no treatment currently exists. »

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

Back to news